Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 725 of 2051 entries
View as:

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Phase: N/A Priority: Normal
NCT ID: NCT01263314 Org: User:
Start: 11/01/10 End: 03/01/11 Due: 03/01/12

Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01181310 Org: User:
Start: 06/30/07 End: 10/31/07 Due: 10/31/08

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Phase: N/A Priority: Normal
NCT ID: NCT03407170 Org: User:
Start: 06/28/18 End: 08/14/19 Due: 08/14/20

V260 Registration Study (V260-013)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00166517 Org: User:
Start: 08/31/05 End: 07/31/06 Due: 07/31/07

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Phase: N/A Priority: Normal
NCT ID: NCT01496170 Org: User:
Start: 12/31/11 End: 06/30/12 Due: 06/30/13

Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

Phase: N/A Priority: Normal
NCT ID: NCT00419367 Org: User:
Start: - End: - Due: -

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092404 Org: User:
Start: 12/31/01 End: 06/30/05 Due: 06/30/06

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Phase: N/A Priority: Normal
NCT ID: NCT05526716 Org: User:
Start: 09/23/22 End: 06/21/23 Due: 06/21/24

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Phase: N/A Priority: Normal
NCT ID: NCT05466422 Org: User:
Start: 09/20/22 End: 07/02/25 Due: 07/02/26

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

Phase: N/A Priority: Normal
NCT ID: NCT03253796 Org: User:
Start: 11/07/17 End: 03/17/21 Due: 03/17/22

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Phase: N/A Priority: Normal
NCT ID: NCT05008224 Org: User:
Start: 10/07/21 End: 05/26/24 Due: 05/26/25

MK0767 in Type 2 Diabetes (0767-012)

Phase: N/A Priority: Normal
NCT ID: NCT00543556 Org: User:
Start: 10/31/01 End: 11/30/03 Due: 11/30/04

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Phase: N/A Priority: Normal
NCT ID: NCT05319730 Org: User:
Start: 05/16/23 End: 09/20/28 Due: 09/20/29

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Phase: N/A Priority: Normal
NCT ID: NCT06643390 Org: User:
Start: 11/21/23 End: 07/10/25 Due: 07/10/26

Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)

Phase: N/A Priority: Normal
NCT ID: NCT00394589 Org: User:
Start: 03/31/06 End: 10/31/08 Due: 10/31/09

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

Phase: N/A Priority: Normal
NCT ID: NCT06698042 Org: User:
Start: 11/21/24 End: 02/11/30 Due: 02/11/31

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

Phase: N/A Priority: Normal
NCT ID: NCT06721156 Org: User:
Start: 12/16/24 End: 05/14/27 Due: 05/14/28

A Study to Evaluate the Effect of Formulation and Food on MK-1084 in Healthy Adult Participants (MK-1084-011)

Phase: N/A Priority: Normal
NCT ID: NCT06942741 Org: User:
Start: 05/13/25 End: 07/03/25 Due: 07/03/26

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Phase: N/A Priority: Normal
NCT ID: NCT01513291 Org: User:
Start: 02/06/12 End: 10/03/12 Due: 10/03/13

3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

Phase: N/A Priority: Normal
NCT ID: NCT01721265 Org: User:
Start: 10/31/12 End: 03/31/15 Due: 03/31/16

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Phase: N/A Priority: Normal
NCT ID: NCT04708041 Org: User:
Start: 03/15/21 End: 10/23/29 Due: 10/23/30

Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)

Phase: N/A Priority: Normal
NCT ID: NCT00796250 Org: User:
Start: 11/01/03 End: 01/01/05 Due: 01/01/06

A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00717860 Org: User:
Start: 08/31/08 End: 07/31/10 Due: 07/31/11

Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)

Phase: N/A Priority: Normal
NCT ID: NCT01678131 Org: User:
Start: 10/30/12 End: 09/02/13 Due: 09/02/14

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Phase: N/A Priority: Normal
NCT ID: NCT00432237 Org: User:
Start: 03/31/07 End: 12/31/07 Due: 12/31/08